Wide Ranks

BNTX

BioNTech SE

120.72

Top Statistics
Market Cap 28 B Forward PE -35.60 Revenue Growth 39.00 %
Current Ratio 7.33 Trailing PE 0.0000 Earnings Growth 22.70 %
Profit Margins -15.36 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -45.45 Enterprise / Revenue 4.10 Price To Sales Trailing12 Months 9.52
Profitability
Profit Margins -15.36 % Operating Margins 1.68 %
Balance Sheet
Total Cash 16 B Total Cash Per Share 69.70 Total Debt 243 M
Total Debt To Equity 1.27 Current Ratio 7.33 Book Value Per Share 79.73
All Measures
Short Ratio 264.00 % Message Board Id finmb_51198843 Fax 49 6131 9084 390
Shares Short Prior Month 2 M Return On Equity -0.0240 City Mainz
Uuid ec5204aa-33b4-3ae1-bc3a-4bb94e6f559d Previous Close 118.54 First Trade Date Epoch Utc 1 B
Book Value 79.73 Beta 0.2590 Total Debt 243 M
Volume 599972 Price To Book 1.51 Fifty Two Week Low 76.53
Total Cash Per Share 69.70 Total Revenue 3 B Shares Short Previous Month Date 1 B
Target Median Price 125.46 Max Age 86400 Recommendation Mean 1.68
Sand P52 Week Change 0.3133 Operating Margins 1.68 % Last Dividend Value 2.11
Target Mean Price 129.50 Net Income To Common -466900000 Short Percent Of Float 0.0495
Implied Shares Outstanding 239 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 16 B
Next Fiscal Year End 1 B Revenue Per Share 12.62 Held Percent Insiders 0.6165
Ebitda Margins -9.03 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 118.54 Target Low Price 115.42
Gmt Off Set Milliseconds -18000000 Fifty Day Average 113.52 Open 119.00
Free Cashflow 1 B Dividend Yield 0.00 % Return On Assets -0.0123
Time Zone Short Name EST Trailing Eps -2.04 Day Low 118.60
Address1 An der Goldgrube 12 Shares Outstanding 239 M Price Hint 2
Target High Price 163.72 Website https://www.biontech.de 52 Week Change 0.2023
Average Volume 1 M Earnings Quarterly Growth 23.40 % Forward Eps -3.90
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 709.90 %
Is_sp_500 False Regular Market Day High 121.51 Profit Margins -15.36 %
Debt To Equity 1.27 Fifty Two Week High 131.49 Day High 121.51
Shares Short 2 M Regular Market Open 119.00 Industry Key biotechnology
Earnings Growth 22.70 % Enterprise To Revenue 4.10 Revenue Growth 39.00 %
Shares Percent Shares Out 0.0103 Operating Cashflow 1 B Currency USD
Time Zone Full Name America/New_York Market Cap 28 B Is_nasdaq_100 False
Zip 55131 Quote Type EQUITY Industry Biotechnology
Ex Dividend Date 1 B Regular Market Day Low 118.60 Held Percent Institutions 0.2065
Long Name BioNTech SE Current Price 120.72 Enterprise To Ebitda -45.45
Financial Currency EUR Current Ratio 7.33 Gross Margins 84.31 %
Industry Disp Biotechnology Number Of Analyst Opinions 18 Country Germany
Float Shares 91 M Two Hundred Day Average 96.26 Enterprise Value 12 B
Price To Sales Trailing12 Months 9.52 Forward PE -35.60 Regular Market Volume 599972
Last Dividend Date 1 B Ebitda -274500000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.

It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases.

It has collaborations with Genentech, Inc.; Sanofi S.

A.

; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co.

, Ltd; and Ryvu Therapeutics S.

A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vaccine ecosystem.

BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.